Inhibition of Molecular Mediators in TNF-Signaling (Inflammation) for the Treatment of Cardiovascular Diseases Such as Atherosclerosis, Stroke, and Ischemia/Reperfusion Injury

Brief Description
Applications:
This technology has identified a molecular mediator of TNF-signaling and subsequent inflammation in endothelial cells.  Pharmacological inhibition of this mediator can be beneficial for the treatment of cardiovascular diseases such as atherosclerosis, stroke, and ischemia/reperfusion injury.

Advantages:
This method for protecting against ischemia and reperfusion damage by inhibiting the interaction between thioredoxin and thioredoxin interacting protein allows increased thioredoxin activity which inhibits downstream events that can cause cardiovascular tissue damage.
Patent Information:
Title Country Patent No. Issued Date
Thioredoxin Interacting Protein (TXNIP) as a Regulator of Vascular Function United States 8,999,944 4/7/2015
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Bradford Berk
Keywords:
Cardiovascular
Therapy